Posted inBiotechnology
Posted inBiotechnology
Rapt re-rolls after flameout, paying $35M for challenger to Novartis, Roche drug
Rapt Therapeutics has charted a new course following the implosion of its lead program, agreeing to pay $35 million for a…












